Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase kinase kinase 5 (MAP3K5), widely known as Apoptosis signal-regulating kinase 1 (ASK1), is a key serine/threonine kinase that functions as an upstream regulator in the mitogen-activated protein kinase (MAPK) signaling cascade. Under physiological conditions, MAP3K5 is kept inactive through its association with reduced thioredoxin (Trx). However, in response to cellular stressors such as oxidative stress, endoplasmic reticulum (ER) stress, and inflammatory cytokines (e.g., TNF-alpha), Trx dissociates, allowing MAP3K5 to undergo homodimerization and autophosphorylation. Once activated, MAP3K5 phosphorylates downstream MAP kinase kinases (MKK3/6 and MKK4/7), which subsequently activate the p38 and JNK pathways to drive apoptosis, inflammation, and fibrosis.
Due to its central role in mediating stress-induced cell death and tissue remodeling, MAP3K5 has emerged as a highly attractive therapeutic target for chronic inflammatory, fibrotic, and degenerative diseases. Small-molecule inhibitors, such as selonsertib (GS-4997), have been developed to target the ATP-binding site of the kinase domain, blocking downstream signaling. Although clinical trials of selonsertib in nonalcoholic steatohepatitis (NASH) and pulmonary arterial hypertension failed to meet primary efficacy endpoints, MAP3K5 inhibition has shown therapeutic potential in slowing the progression of diabetic kidney disease (DKD). Notable clinical challenges include a transient, benign increase in serum creatinine due to the inhibition of renal creatinine transporters, which can confound early assessments of kidney function.
ATP-competitive inhibition of the catalytic kinase domain of MAP3K5/ASK1, preventing its autophosphorylation and downstream phosphorylation of MKK3/MKK6 and MKK4/MKK7, thereby blocking the activation of p38 MAPK and JNK signaling pathways.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase 5 (MAP3K5).